COMMUNIQUÉS West-GlobeNewswire

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
12/11/2025
ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts: ORKA [...]
GE HealthCare and RadNet’s DeepHealth Division Sign Letter of Intent to Advance Innovation and Adoption of AI-Powered Imaging Across Multiple Modalities and Remote Scanning
12/11/2025
Collaboration aims to expand existing U.S. relationship combining GE HealthCare’s mammography systems with DeepHealth’s Breast Suite to include a worldwide distribution arrangement Intends to integrate GE HealthCare’s [...]
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
12/11/2025
Completed strategic pivot from R&D focus to commercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relations Advanced multiple [...]
Kura Oncology to Participate in Upcoming Investor Conference
12/11/2025
SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
12/11/2025
- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with [...]
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
12/11/2025
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to [...]
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
12/11/2025
Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive interim Phase 2 data [...]
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
12/11/2025
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
12/11/2025
Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, [...]
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
12/11/2025
Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M Announced strategic [...]
BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
12/11/2025
MELVILLE, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
12/11/2025
BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced [...]
Nusano Receives Innovation Impact Award from BioUtah
12/11/2025
Company’s radioisotope production platform recognized for potential impact on next-generation cancer diagnostics and therapeutics SALT LAKE CITY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company enabling [...]
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
12/11/2025
Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026 New Data Show Bemnifosbuvir Has Unique Dual Mechanism Against [...]
Glass House Brands Reports Third Quarter 2025 Financial Results
12/11/2025
Third quarter results reflect temporary planned scaled back in new planting and wholesale production Company remains on track to return to full production at existing greenhouses in the first quarter of 2026, by year- [...]
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
12/11/2025
– Hosted Virtual R&D Day Highlighting GPS and SLS009 Programs in AML – – Positive Phase 2 Data for SLS009 in R/R AML Accepted for Presentation at ASH 2025; Initiation of Trial Including Newly Diagnosed First-Line [...]
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
12/11/2025
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
12/11/2025
Positive randomized 3-month REMAIN-1 Midpoint Cohort data showed single Revita procedure maintained weight loss after GLP-1 discontinuation; 6-month data expected in Q1 2026 6-month data from open-label REVEAL-1 Cohort [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
12/11/2025
Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest [...]

Pages